Madrigal Pharmaceuticals (MDGL) Other Non Operating Income (2025 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Other Non Operating Income of -$795000.0 for Q2 2026, down 1792.86% year-over-year from $46962.0 in Q2 2025, and up 62.0% quarter-over-quarter from -$2.1 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Other Non Operating Income (2025 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Other Non Operating Income for 2 consecutive years, with -$795000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non Operating Income fell 1792.86% year-over-year to -$795000.0; the TTM figure through Jun 2026 stood at -$5.7 million (down 13390.48% YoY), while the FY2025 annual figure was -$2.8 million, changed N/A from the prior year.
- Other Non Operating Income grew to -$795000.0 in Q2 2026 per MDGL's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at -$42000.0 in Q2 2025 and bottomed at -$2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -795,000.00 |
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | -2.47 Mn |
| Sep 30, 2025 | -293,000.00 |
| Jun 30, 2025 | -42,000.00 |